title: Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner.
abstract: In this behavioural and pharmacological study in male CCK2 receptor-deficient mice (CCK2(-/-)), we evaluated the role of the interaction of endocannabinoids (eCBs) and cholecystokinin (CCK) on the regulation of anxiety-related and motor behaviours. Repeated treatment with amphetamine (2mg/kg daily for four days) induced slightly weaker motor sensitisation in CCK2(-/-) mice compared to their wild-type (CCK2(+/+)) littermates. Co-administration of rimonabant (1mg/kg) with amphetamine antagonised the development of motor sensitisation in CCK2(+/+) mice. However, we did not find a similar effect of rimonabant in CCK2(-/-) mice. We did not find any differences between the behaviour of CCK2(+/+) and CCK2(-/-) mice in models designed to assess emotional behaviours (dark/light exploration, marble burying and conditioned place aversion). This study supports the hypothesis that eCBs play a role in the development of amphetamine-induced sensitisation. Moreover, we have demonstrated that intact CCK2 receptors are necessary for the development of eCB-mediated sensitisation to amphetamine.
authors.affiliation: Department of Physiology, University of Tartu, Ravila 19, Tartu 50411, Estonia. kertu.runkorg@ut.ee
authors.forename: Kertu
authors.initials: K
authors.lastname: Rünkorg
authors.forename: Laura
authors.initials: L
authors.lastname: Orav
authors.forename: Sulev
authors.initials: S
authors.lastname: Kõks
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Matsui
authors.forename: Vallo
authors.initials: V
authors.lastname: Volke
authors.forename: Eero
authors.initials: E
authors.lastname: Vasar
mesh_terms: D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology*; D043887:Receptor, Cholecystokinin B / Q000235:genetics* / Q000378:metabolism; D000077285:Rimonabant
chemical_list: D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D000697:Central Nervous System Stimulants; D010880:Piperidines; D011720:Pyrazoles; D043887:Receptor, Cholecystokinin B; D000661:Amphetamine; D000077285:Rimonabant